Vaxart, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Vaxart, Inc. (VXRT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.50% for the 12-month period ending 2025-12-31, per its S-1 filed 2026-05-08.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-05-08
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2018 was -2.10%.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2017 was -1.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | -0.50% S-1 · filed 2026-05-08 |
| 2024-12-31 | -0.10% S-1 · filed 2026-05-08 |
| 2018-12-31 | -2.10% 10-K · filed 2019-02-06 |
| 2017-12-31 | -1.40% 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |